CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.On Monday, William Blair initiated coverage on CareDx Inc., citing that the company is turning the page on a tumultuous recent chapter.Analyst Andrew F. Brackmann said the company is “getting back to consistency and predictability, and leaving behin ...